Patents by Inventor Aida Inbal

Aida Inbal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9023609
    Abstract: The present invention reveals a strong correlation between FGL-2 prothrombinase activity levels and the presence of a malignant proliferative disorder in a subject. Thus, the present invention provides FGL-2 prothrombinase activity as a diagnostic tool for malignancy.
    Type: Grant
    Filed: July 11, 2011
    Date of Patent: May 5, 2015
    Assignees: Mor Research Applications Ltd., Ramot at Tel-Aviv University Ltd.
    Inventors: Aida Inbal, Esther Rabizadeh
  • Publication number: 20130115645
    Abstract: The present: invention reveals a strong correlation between FGL-2 prothrombinase activity levels and the presence of a malignant proliferative disorder in a subject. Thus, the present invention provides FGL-2 prothrombinase activity as a diagnostic tool for malignancy.
    Type: Application
    Filed: July 11, 2011
    Publication date: May 9, 2013
    Applicants: RAMOT AT TEL-AVIV UNIVERSITY LTD., MOR RESEARCH APPLICATIONS LTD.
    Inventors: Aida Inbal, Esther Rabizadeh
  • Publication number: 20070167361
    Abstract: Subject of the present invention is the use of a Factor XIII-preparation preferably in injectable form for the treatment of diseases which are associated with disturbed blood perfusion of the tissue following transient or permanent ischemia.
    Type: Application
    Filed: February 15, 2005
    Publication date: July 19, 2007
    Inventors: Aida Inbal, Rima Dardik, Jonathan Leor, Gerhard Dickneite
  • Patent number: 6489290
    Abstract: This invention combines the unique antiplatelet effects of S-nitrosothiols and the antiadhesive properties of fragments of von Willebrand (vWF) in the A1 domain to provide unique molecules that exploit both of these properties. Preferred molecules comprise a fragment of A1 (Ala 444-Asn 730) in which arginine at position 545 is replaced by cysteine (the most frequent von Willebrand disease type 2b mutation) that has been discovered to impair platelet adhesion, and to inhibit an antithrombotic activity in vivo. This cysteine residue may be S-nitrosated to produce a novel molecule that has the potential for impairing platelet adhesion as well as activation/aggregation, and such molecules form the basis of a novel therapeutic method for impairing platelet responses following vascular injury or in other thrombotic disorders according to this invention.
    Type: Grant
    Filed: December 7, 1999
    Date of Patent: December 3, 2002
    Assignee: Trustees of Boston University
    Inventors: Joseph Loscalzo, Aida Inbal
  • Publication number: 20020123457
    Abstract: This invention combines the unique antiplatelet effects of S-nitrosothiols and the antiadhesive properties of fragments of vWF in the A1 domain to provide unique molecules that exploit both of these properties. Preferred molecules comprise a fragment of A1 (ala444-asp73O) in which arginine at position 545 is replaced by cysteine (the most frequent von Willebrand disease type 2b mutation) that has been discovered to impair platelet adhesion, and to exhibit antithrombotic activity in vivo. This cysteine residue may be S-nitrosated to produce a novel molecule that has the potential for impairing platelet adhesion as well as activation/aggregation, and such molecules form the basis of a novel therapeutic method for impairing platelet responses following vascular injury or in other thrombotic disorders according to this invention.
    Type: Application
    Filed: December 7, 1999
    Publication date: September 5, 2002
    Inventors: JOSEPH LOSCALZO, AIDA INBAL